Senology Newsletter - October 2, 2012
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Senology Newsletter - October 2, 2012

  • 318 views
Uploaded on

Latest Advances in Clinical Senology and Oncology

Latest Advances in Clinical Senology and Oncology

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
318
On Slideshare
318
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Senology Newsletter Page 1 of 3 Senology.org - Newsletter International Senologic and Oncologic  Scientific Community (ISOSC)  "Connecting specialists worldwide" Editor-in-Chief: Gian Paolo Andreoletti, MD Subscribe Unsubscribe Contact Back Issues Connecting Specialists Worldwide Join us on LinkedIn, Twitter, Facebook, ResearchGate, Doctorsbook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for real-time updates de Koning H: "A tribute to Stefano Ciatto (2 June 1949-4 May 2012)", J Med Screen. 2012 Sep 8. [Epub ahead of print] Literature Selection The Cancer Genome Atlas Network : "Comprehensive molecular portraits of human breast tumours", Nature. 2012 Sep 23. [Epub ahead of print] Pijpe A et al.: "Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)", BMJ. 2012 Sep 6;345:e5660. doi: 10.1136/bmj.e5660 Falck AK et al.: "Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study", BMC Cancer. 2012 Sep 11;12 (1):403. [Epub ahead of print] Maaskant-Braat AJ et al.: "Sentinel Node and Recurrent Breast Cancer (SNARB): Results of a Nationwide Registration Study", Ann Surg Oncol. 2012 Sep 1. [Epub ahead of print] Solà M et al.: "Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000", Ann Surg Oncol. 2012 Sep 7. [Epub ahead of print] Iwata H et al.: "Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer", Cancer. 2012 Sep 12. doi: 10.1002/cncr.27818. [Epub ahead of print] Karasawa K et al.: "Comparison of hypofractionated and conventionally fractionated whole-breast irradiation for early breast cancer patients: a single-institute study of 1,098 patients", Breast Cancer.file://C:Documents and SettingsutenteDesktopNewsl_Oct2012.htm 02/10/2012
  • 2. Senology Newsletter Page 2 of 3 2012 Sep 12. [Epub ahead of print] Cramer H et al.: "Yoga for breast cancer patients and survivors: a systematic review and meta- analysis", BMC Cancer. 2012 Sep 18;12(1):412. [Epub ahead of print] Comment "The European breast screening programmes are preventing large numbers of breast cancer deaths" , Mireille Broeders, Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands "After considering all published data from European studies, the reduction in breast cancer mortality associated with mammographic population-based service screening programmes is in the range of 25–31% for women invited for screening and 38–48% for women actually screened with sufficient follow-up time. It appears that much of the current controversy surrounding the value of mammography screening is due to the use of inappropriate methodological approaches that are unable to capture the true effect of mammographic screening. Overall, the results of this first comprehensive review of European breast screening services show that for every 1,000 women screened every two years from the age of 50 to the age of about 68-69, between seven and nine lives would be saved, and four cases would be over-diagnosed. The European breast screening programmes are preventing large numbers of breast cancer deaths, and the benefits outweigh the harms of screening. The programmes should continue to provide high quality screening services and should work towards achieving targets on coverage, uptake and assessment rates. In addition, communication methods should be improved in order to raise women’s awareness, and to make information on the pros and cons of breast cancer screening more accessible, relevant and comprehensible" (Commentary on: Broeders M et al.: "The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies ", J Med Screen 2012 Sep: 19(1): 14-25) "Review of breast cancer screening programs in Europe: lives saved by screening outweigh over- diagnosed cases by a factor of two to one" - Share your opinion on LinkedIn® Calendar of Events 12th Michelangelo Foundation Seminar: “Moving from adjuvant to neoadjuvant trials for development of new therapies in breast cancer: a hopeless heresy or a feasible paradigm shift?”, October 12, 2012 Milan, Italy 17th World Congress on Breast Diseases of the Senologic International Society, -SIS, October 10-13, 2012, Salvador, Bahia, Brazil Breast Cancer in Young Women Conference, 8-10 November 8-10, 2012, Dublin, Ireland IBUS - International Breast Ultrasound Course, 13 - 15 November 2012, Tel Aviv, Israel 8th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC), November 15-17, 2012, Padova , Italy - with the Patronage of Senology.org 2012 CTRC-AACR San Antonio Breast Cancer Symposium , December 4-8, 2012, San Antonio, TX, USA Literature Selection Stoffels I et al.: "Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma", JAMA. 2012 Sep 12;308(10):1007-14 The Cancer Genome Atlas Research Network: "Comprehensive genomic characterization of squamous cell lung cancers", Nature. 2012 Sep 9. doi: 10.1038/nature11404. [Epub ahead of print] Moyer VA et al.: "Screening for Ovarian Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement", Ann Intern Med. 2012 Sep 11 [Epub ahead of print] Huang ZM et al.: "Minimally invasive therapies have good survival rate for patients with unresectable pancreatic cancer", Chin J Cancer. 2012 Sep 10. doi: 10.5732/cjc.012.10093. [Epub ahead of print] Uehara T et al.: "H. pylori Infection Is Associated with DNA Damage of Lgr5-Positive Epithelial Stem Cells in the Stomach of Patients with Gastric Cancer", Dig Dis Sci. 2012 Sep 4. [Epub ahead of print] Kennedy TJ et al.: "Laparoscopic radiofrequency ablation for the management of colorectal liver metastases: 10-year experience", J Surg Oncol. 2012 Sep 20 [Epub ahead of print] Lacson JC et al.: "Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk", Cancer. 2012 Sep 10. doi: 10.1002/cncr.27554. [Epub ahead of print] Fragments of Historyfile://C:Documents and SettingsutenteDesktopNewsl_Oct2012.htm 02/10/2012
  • 3. Senology Newsletter Page 3 of 3 1914 - Proposal by Theodor Boveri (Bamberg, 1862 - Wurzburg, 1915) that cancer can be triggered by chromosomal mutations Literature Selection Pavone ME et al.: "Aromatase inhibitors for the treatment of endometriosis", Fertil Steril. 2012 Sep 19 [Epub ahead of print] Zeng XT et al.: "Passive Smoking and Cervical Cancer Risk: A Meta-analysis Based on 3,230 Cases and 2,982 Controls", Asian Pac J Cancer Prev. 2012;13(6):2687-93 Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the Expert Q&A Workshops and join the conversation. Q&A of the month "What is the current status of targeted therapies for ovarian cancer?" "Currently the only targeted therapy routinely employed in ovarian cancer is directed at the cancer- associated blood vessels. The term, “anti-angiogenesis”, is employed to describe this therapeutic concept. The drug, bevacizumab, has been shown to be helpful in some patients when used alone (single agent therapy) or employed in combination with certain chemotherapeutic agents. Other targeted therapies remain under active clinical investigation (for example, PARP inhibitors), but have not at this point in time been approved for routine use by the FDA outside the confines of clinical trials" (Answer by Maurie Markman, Cancer Treatment Centers of America, USA) Stay informed.... Recent Advances in Clinical Medicine Gold R et al.: "Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis ",N Engl J Med. 2012 Sep 20;367(12):1098-107 Unsubscribe       www.senology.orgfile://C:Documents and SettingsutenteDesktopNewsl_Oct2012.htm 02/10/2012